# To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

> **NCT06821698** · PHASE1 · COMPLETED · sponsor: **Kaken Pharmaceutical** · enrollment: 38 (actual)

## Conditions studied

- Healty Volunteers

## Interventions

- **DRUG:** KP-001
- **DRUG:** Rosuvastatin calcium10mg
- **DRUG:** Caffeine citrate
- **DRUG:** Fluvoxamine

## Key facts

- **NCT ID:** NCT06821698
- **Lead sponsor:** Kaken Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-13
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821698, "To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06821698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*